276 related articles for article (PubMed ID: 21483698)
21. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
[TBL] [Abstract][Full Text] [Related]
23. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
Anal Bioanal Chem; 2012 Jun; 403(7):1841-50. PubMed ID: 22447217
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
Caetano-Pinto P; Jamalpoor A; Ham J; Goumenou A; Mommersteeg M; Pijnenburg D; Ruijtenbeek R; Sanchez-Romero N; van Zelst B; Heil SG; Jansen J; Wilmer MJ; van Herpen CML; Masereeuw R
Mol Pharm; 2017 Jun; 14(6):2147-2157. PubMed ID: 28493713
[TBL] [Abstract][Full Text] [Related]
25. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
26. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.
Deguchi T; Ohtsuki S; Otagiri M; Takanaga H; Asaba H; Mori S; Terasaki T
Kidney Int; 2002 May; 61(5):1760-8. PubMed ID: 11967025
[TBL] [Abstract][Full Text] [Related]
27. Protein-Bound Uremic Toxins in Hemodialysis Patients Relate to Residual Kidney Function, Are Not Influenced by Convective Transport, and Do Not Relate to Outcome.
van Gelder MK; Middel IR; Vernooij RWM; Bots ML; Verhaar MC; Masereeuw R; Grooteman MP; Nubé MJ; van den Dorpel MA; Blankestijn PJ; Rookmaaker MB; Gerritsen KGF
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32272776
[TBL] [Abstract][Full Text] [Related]
28. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
29. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Mol Pharmacol; 2004 May; 65(5):1208-16. PubMed ID: 15102949
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.
Zhao R; Raub TJ; Sawada GA; Kasper SC; Bacon JA; Bridges AS; Pollack GM
Drug Metab Dispos; 2009 Jun; 37(6):1251-8. PubMed ID: 19273529
[TBL] [Abstract][Full Text] [Related]
31. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
[TBL] [Abstract][Full Text] [Related]
33. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
[TBL] [Abstract][Full Text] [Related]
34. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
35. Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.
Tsujimoto M; Hatozaki D; Shima D; Yokota H; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Ther Apher Dial; 2012 Dec; 16(6):580-7. PubMed ID: 23190519
[TBL] [Abstract][Full Text] [Related]
36. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
[TBL] [Abstract][Full Text] [Related]
37. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
Sugimoto Y; Tsukahara S; Imai Y; Sugimoto Y; Ueda K; Tsuruo T
Mol Cancer Ther; 2003 Jan; 2(1):105-12. PubMed ID: 12533678
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a multiple endogenously expressed adenosine triphosphate-binding cassette transporters using nuclear and cellular membrane affinity chromatography columns.
Habicht KL; Singh NS; Khadeer MA; Shimmo R; Wainer IW; Moaddel R
J Chromatogr A; 2014 Apr; 1339():80-85. PubMed ID: 24642394
[TBL] [Abstract][Full Text] [Related]
39. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.
Lemos C; Kathmann I; Giovannetti E; Beliën JA; Scheffer GL; Calhau C; Jansen G; Peters GJ
Mol Cancer Ther; 2009 Mar; 8(3):655-64. PubMed ID: 19240161
[TBL] [Abstract][Full Text] [Related]
40. Sulfation disposition of liquiritigenin in SULT1A3 overexpressing HEK293 cells: The role of breast cancer resistance protein (BCRP) and multidrug resistance-associated protein 4 (MRP4) in sulfate efflux of liquiritigenin.
Liu T; Zhang X; Zhang Y; Hou J; Fang D; Sun H; Li Q; Xie S
Eur J Pharm Sci; 2018 Nov; 124():228-239. PubMed ID: 30176366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
